EPHA7 and cancer: After adjusting confounding factors (sex, age, cancer type, drug class, and TMB level), EPHA7-MUT patients achieved significantly longer OS than EPHA7-WT patients in the validation cohort (median OS: not reach [NR] vs 17 months, HR = 0.62 [95% CI, 0.39–0.97], log-rank test P = 0.0001, multivariable adjusted P = 0.0367) (Fig. 3a).